echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The clinical results of the A3AR agonist introduced by CMS disclosed the original research company's share price soared 73%

    The clinical results of the A3AR agonist introduced by CMS disclosed the original research company's share price soared 73%

    • Last Update: 2021-12-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Shi Bei

    On December 20, Can-Fite announced that in the open-label extension trial part of the Phase II study of Namodenoson for the treatment of hepatocellular carcinoma (HCC), the last patient received the treatment achieved complete remission (CR), which means this All cancer lesions of the patient were removed


    After receiving namodenson treatment, the patient has been alive for 5 years.


    Namodenoson is a highly selective, oral small molecule A3 adenosine receptor (A3AR) agonist.


    Can-Fite is expected to start the recruitment of Namodenoson's key Phase III trial patients in the first quarter of 2022 for the treatment of advanced HCC patients with potential Child Pugh B7 (CPB7) liver cirrhosis to support the submission of new drug applications (NDA) and Approved


    It is worth noting that in August 2018, CMS reached an authorized cooperation with Can-Fite with an advance payment of US$2 million, a milestone payment of US$72.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.